SCHEDULE OF ANTI-DILUTIVE IMPACT ON NET LOSSES |
SCHEDULE OF ANTI-DILUTIVE IMPACT ON NET LOSSES
| |
2025 | | |
2024 | |
| |
March 31, | |
| |
2025 | | |
2024 | |
Stock warrants | |
| 125,531 | | |
| 696,955 | (1) |
Stock options | |
| 236,250 | | |
| - | |
Common shares issuable upon conversion of convertible notes | |
| - | | |
| 234,376 | |
Common shares issuable upon conversion of Preferred Series A | |
| - | | |
| 1,500,000 | |
Common shares issuable upon conversion of Preferred Series B | |
| - | | |
| 1,310,000 | |
Total | |
| 361,781 | | |
| 3,741,331 | |
(1) |
Does
not include Representative warrants issued to underwriter for 51,000, which are not exercisable until March 1, 2025. |
|
SCHEDULE
OF ANTI-DILUTIVE IMPACT ON NET LOSSES
| |
2024 | | |
2023 | |
| |
December 31, | |
| |
2024 | | |
2023 | |
Stock warrants (1) | |
| 125,531 | | |
| 611,017 | |
Stock options | |
| 322,500 | | |
| - | |
Common stock issuable upon conversion of convertible notes | |
| - | | |
| 148,438 | |
Common shares issuable upon conversion of Series A Preferred | |
| - | | |
| 1,500,000 | |
Common shares issuable upon conversion of Series B Preferred | |
| - | | |
| 1,310,000 | |
Total | |
| 448,031 | | |
| 3,569,455 | |
(1) |
Does
not include Representative warrants issued to underwriter for 51,000, which are not exercisable until March 1, 2025. |
|